Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer

Xenobiotica

Volumn 43, Issue 5, 2013, Pages 443-453

  Deng, Yanli ^a   Sychterz, Caroline ^a   Suttle, A Benjamin ^a   Dar, Mohammed M ^a   Bershas, David ^a   Negash, Kitaw ^a   Qian, Yanwen ^a   Chen, Emile P ^a   Gorycki, Peter D ^a   Ho, May Y K ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Absorption; Bioavailability; Excretion; Human; Metabolism; Pazopanib; Pharmacokinetics

Indexed keywords

CARBON 14; DRUG METABOLITE; PAZOPANIB;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DEMETHYLATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; RADIOACTIVITY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URINARY EXCRETION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARBON RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES;

EID: 84875828632     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.734642     Document Type: Article

References (11)

1. Carmeliet P, Jain RK. (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
2. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. (2001). Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 8: 260-267. (Pubitemid 32294808)
3. CHMP assessment report for Votrient, 2010. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Public-assessment-report/human/001141/WC500094275. pdf. 10 October 2012.
4. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095. (Pubitemid 23211439)
5. GlaxoSmithKline (revised, 2012) Votrient (pazopanib). Prescribing information. GlaxoSmithKline, Research Triangle Park, NC 27709.
6. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L. (2009). Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15: 4220-4227.
7. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M. (2007). Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6: 2012-2021. (Pubitemid 47052491)
8. Pakos EE, Goussia AC, Tsekeris PG, Papachristou DJ, Stefanou D, Agnantis NJ. (2005). Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 25: 3591-3596. (Pubitemid 41105246)
9. Sonpavde G, Hutson TE, Sternberg CN. (2008). Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 17: 253-261. (Pubitemid 351578205)
10. Wang J, Coltrera MD, Gown AM. (1994). Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study. Cancer Res 54: 560-564.
11. Yudoh K, Kanamori M, Ohmori K, Yasuda T, Aoki M, Kimura T. (2001). Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 84: 1610-1615. (Pubitemid 32612491)